GlaxoSmithKline Plc (GSK.L) plans to launch a campaign to replace the entire board of Human Genome Sciences Inc (HGSI.O) with its own nominees, stepping up its $2.6 billion hostile bid for the U.S. biotech company, sources familiar with the situation said on Wednesday. The British company has started reaching out to executives in the pharmaceutical industry as well as finance and governance experts who could be nominated as independent directors on Human Genome’s 12-member board, they said.
